Respiratory Tract Infections clinical trials

Explore recruiting respiratory tract infections clinical trials.

Recruiting respiratory tract infections studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Respiratory Tract Infections trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

OM85 in the prevention of respiratory infections in elderly patients at risk

Italy

Therapeutic use (Phase IV) EU CTIS Study details

RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, TWO-ARMS, MULTICENTER, POST AUTHORIZATION EFFICACY AND SAFETY STUDY (PAES) TO CONFIRM AND COLLECT MORE CLINICAL DATA OF BUCCALIN® TABLETS IN THE PROPHYLAXIS OF RECURRENT LOWER RESPIRATORY TRACT INFECTIONS (RLRTIs).

Italy

Therapeutic use (Phase IV) EU CTIS Study details

A randomized double-blind placebo-controlled study to demonstrate the efficacy of PMBL® sublingual tablets in reducing the incidence of respiratory tract infections in children aged 3-12 years (PIRTIK).

Poland

Therapeutic use (Phase IV) EU CTIS Study details

A Randomised, Placebo-Controlled, 3-Arm, Double-Blind, Multicentre, Phase 4 Study to Assess the Efficacy of OM-85 (Broncho Vaxom) Short- and Long-Term Treatment vs. Placebo in the Prevention of Respiratory Tract Infections in Children Aged Between 6 Months and 5 Years with Wheezing Lower Respiratory Illness

Hungary, Germany, Poland, Italy

Therapeutic use (Phase IV) EU CTIS Study details

Tailoring antibiotic duration for respiratory tract infections in primary care. A pragmatic randomised clinical trial [STORM Study]

Spain

Therapeutic use (Phase IV) EU CTIS Study details

CLARITHROMYCIN TO PREVENT SECONDARY INFECTIONS IN PATIENTS WITH SEPSIS FOLLOWING LOWER RESPIRATORY TRACT INFECTIONS: THE CLASSIFY TRIAL

Greece

Therapeutic confirmatory (Phase III) EU CTIS Study details

Respiratory Tract Infections trials by city

Respiratory Tract Infections in Toronto Respiratory Tract Infections in Vancouver Respiratory Tract Infections in Montreal Respiratory Tract Infections in Calgary Respiratory Tract Infections in Edmonton Respiratory Tract Infections in Ottawa Respiratory Tract Infections in Winnipeg Respiratory Tract Infections in Quebec City Respiratory Tract Infections in Hamilton Respiratory Tract Infections in Kitchener Respiratory Tract Infections in London Respiratory Tract Infections in Halifax Respiratory Tract Infections in New York Respiratory Tract Infections in Los Angeles Respiratory Tract Infections in Chicago Respiratory Tract Infections in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease